С. difficile infection: clinical and pharmacoeconomic assessment of treatment regimens in antibiotic-associated diarrhea

Abstract

This paper provides a review of the largest studies (over the period of 2017 to 2022) on cost-effectiveness analysis of the recommended treatment algorithms for Clostridioides difficile infection in patients with antibiotic-associated diarrhea (AAD), including pseudomembranous colitis. The review showed that professional medical societies in Russia, EU and US as well as meta-analyses consistently consider vancomycin as the most important treatment option for AAD and pseudomembranous colitis. The role of metronidazole and fidaxomicin in the treatment of AAD is considered ambiguous. Teicoplanin is recommended for using more commonly based on cost-effectiveness analysis.

Keywords

• clostridioides difficile
• antibiotic-associated diarrhea
• treatment
• vancomycin
• metronidazole
• teicoplanin
• costeffectiveness